Jeanne Pinder - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Jeanne Pinder's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Jeanne Pinder

Jeanne Pinder

Verified

Founder, CEO and Editor in Chief, ClearHealthCosts

New York

Journalist Type

-

Seniority Positions

-

Industries

Medium Formats

-

Content

Total articles 516

  • Patients cut off from cheaper obesity drugs as the F.D.A. halts sales of copycats

    By Jeanne Pinder| ClearHealthCosts@ “Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs,” Rebecca Robbins and Dani Blum write over at The New York Times. “The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound.

    By Jeanne Pinder · ClearHealthCosts

    Apr. 16, 2025

  • Medicare Advantage growth slows, even as payments rise

    By Jeanne Pinder| ClearHealthCosts@ The headlong growth in Medicare Advantage, the privatized version of the traditional Medicare program for older and disabled adults, has slowed, even as the prices paid to Medicare Advantage insurers have risen. “With more than half of Medicare-eligible individuals in Medicare Advantage plans, the market grew by 1.3 million (+3.9%),” a recent report from the analytics firm Chartis said.

    By Jeanne Pinder · ClearHealthCosts

    Apr. 14, 2025

  • Patients cut off from cheaper obesity drugs as the F.D.A. halts sales of copycats

    By Jeanne Pinder| ClearHealthCosts@ “Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs,” Rebecca Robbins and Dani Blum write over at The New York Times. “The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound.

    By Jeanne Pinder · ClearHealthCosts

    Apr. 16, 2025

As seen in

Company Info

ClearHealthCosts

Our mission is telling people what things cost in health care, a traditional mystery. Shouldn't you know that your MRI could cost as little as $450 or as much as $6,000? Shouldn't you be able to know other health costs, too? We're here to help. People are coming to us as a trusted space for pricing information. We are a trusted space because we are transparent. The New York Times is calling us the kayak.com of health care. We're using tools like shoe-leather reporting, crowdsourcing, curation and sourcing of pricing databases and cool data visualization and interactivity.

New York, United States

+1 914-552-9876